Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Scientists divide the reversal of liver disease in a new test
Arun Sodyal, MD, Director of the VCU Stravitz-Sanyal Institute for liver disease and metabolic health, discusses a clinical trial that includes 800 participants, in which the semaglutide dose was effective in treating fatty liver diseases.
Use semaglutide injectionsScientists have been able to reverse the life of a dangerous cases of liver disease in a new clinical trial published in the New England Journal of Medicine.
Semaglutide, which is a traditional treatment of type 2 diabetes, has been given to participants who have been diagnosed with life -threatening liver disease called metabolic dysfunction associated with steatohepatitis (mash).
“This is the main step forward on the field,” said Arun Sanyal, MD, Director of the VCU Stravitz-Sanyal Institute for liver disease and metabolic health, in a video from VCU. “Provides patients with an additional choice when we think about treatment Fatty liver disease. “
Joe Rogan gave up drinking alcohol for this simple reason
Mash is a serious form of metabolic dysfunction of related steatotic liver disease (Masld), which was previously known as a non -alcoholic fatty liver disease, according to Webmd.
Mash is a serious form of metabolic dysfunction associated steatotic liver disease (Masld), which was previously known as a non -alcoholic fatty liver disease. (East)
Both Mash and Masld are marked by excessive fat in the liver, which can be dangerous.
“Over time, the accumulation of fat in the liver can lead to inflammation, the fibrosis of the liver, cirrhosis and liver cancer,” the Study Reclamation said.
First GLP-1 weight loss tablet, diabetes shows success in a late-phase test
Researchers have decided to explore semaglutide as a potential treatment, as it has previously shown that this drug class reduces fat and liver scars for people with MASH.
Between 2021 and 2023, 800 randomly selected participants in 37 countries received semaglutide or placebo injections, according to a statement. More than half Type 2 diabetes and about 75% was obese.
Participants treated with semaglutide had improvements in liver enzymes and other blood fibrosis measures, along with 10.5% weight loss. (East)
After 72 weeks of treatment, 62.9% of participants had less inflammation and fat accumulation in the liver.
Only 34.3% of participants in the placebo group had a reduction in symptoms.
“The liver actually starts to look significantly better under the microscope in these patients,” Sanyal remarked.
Ground, other semaglutides associated with hair loss: Here’s what to know
Researchers also found that 36.8% of the Semaglutide group recorded improvements in liver fibrosis, as opposed to 22.4% in the placebo group.
Participants treated with semaglutide also saw improvements in liver enzymes and blood liver fibrosis measures as well as 10.5% weight loss.
“I have been working with GLP-1 treatments for 16 years and these results have been extremely exciting.”
Some harmful experiences were more common in the semaglutide group, including nausea, diarrhea, constipation and vomiting.
“New Nordisk continues to explore semaglutide through metabolism and cardiovascular healthIncluding MASH, the situation with limited treatment capabilities for patients and healthcare professionals, “said Anna Windle, a doctorate, a senior Vice -President of Clinical Development, Medical and Regulatory Affairs in Novo Nordisk, Orempic and Wegovy manufacturer, in a statement for the Fox News Digital.
Click here to sign up for our Health Bulletin
“They encourage us to find these published in Nejm -ui what this might mean for patients. Based on this information, we look forward to working with regulatory bodies to bring this potential new treatment opportunity for patients.”
“Although these results have to be treated with caution, the analysis shows that semaglutide can be an effective tool for treating this advanced liver disease,” said the test leader. (East)
“Although these results have to be treated with caution, the analysis shows that semaglutide can be an effective tool for treating these advanced liver diseases,” said Chief Researcher Philip Newsome, director of liver studies Roger Williams at King’s College London.
Click here to get the Fox News app
“I have been working with GLP-1 treatments for 16 years and these results have been extremely exciting,” he added.
Sanyal noted that previously proved to be semaglutide useful for obesitydiabetes and heart disease.
“Now we can add liver disease to that list.”
For more health articles visit www.foxnews.com/health/health
Looking in advance, the research team plans collect data Of the nearly 1,200 participants in 37 countries to five years to determine the impact of semaglutides on long -term liver complications.
